(9H-xanthene-9-carbonyl)carbamic acid butyl ester: a metabotropic glutamate receptor 2 agonist; structure in first source
ID Source | ID |
---|---|
PubMed CID | 9949202 |
SCHEMBL ID | 3727778 |
MeSH ID | M0575639 |
Synonym |
---|
gtpl1387 |
ro-67-4853 |
ro67-4853 |
butyl n-(9h-xanthene-9-carbonyl)carbamate |
FT-0674449 |
carbamic acid, (9h-xanthen-9-ylcarbonyl)-, butyl ester |
302841-89-0 |
RQBUXEUMZZQUFY-UHFFFAOYSA-N |
(9h-xanthene-9-carbonyl)-carbamic acid butyl ester |
SCHEMBL3727778 |
AKOS024458108 |
ro 67-4853 |
(9h-xanthen-9-ylcarbonyl)-carbamic acid butyl ester |
butyl 9h-xanthene-9-carbonylcarbamate |
DTXSID70433240 |
ro 67-4853, >=98% (hplc) |
J-017858 |
NCGC00370922-01 |
Q7339207 |
carbamic acid, n-(9h-xanthen-9-ylcarbonyl)-, butyl ester |
HY-107506 |
butyl n-(9h-xanthen-9-ylcarbonyl)carbamate |
qm27l9q3rz , |
CMA84189 |
CS-0028663 |
(9h-xanthene-9-carbonyl)carbamic acid butyl ester |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
G | Vesicular stomatitis virus | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Interferon beta | Homo sapiens (human) | Potency | 1.8999 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346276 | Rat mGlu1 receptor (Metabotropic glutamate receptors) | 2001 | Proceedings of the National Academy of Sciences of the United States of America, Nov-06, Volume: 98, Issue:23 | Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 3 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.15) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |